Merck Loses Bid To Revive Antibiotic Patent In Fed. Circ.
The Federal Circuit on Thursday held firm in its decision to invalidate a patent covering Merck's antibiotic Invanz, which was being challenged by Pfizer Inc. unit Hospira, despite arguments from Merck...To view the full article, register now.
Already a subscriber? Click here to view full article